People who have had an ischemic stroke are often forced to take blood thinning medications to reduce the risk of recurrent stroke. The main cause of ischemia is blood clots forming in the vessels, which disrupt their patency.
Scientists from Japan have developed and tested an experimental vaccine on mice, whose task is to reduce the risk of recurrent stroke. They found that the vaccine is able to prevent the formation of blood clots in mice for two months without increasing the risk of bleeding and without causing an autoimmune response. The absence of an autoimmune reaction is important because it means that the body does not perceive the injected vaccine as something foreign.
The overall effect of the vaccine approximately corresponds to the action of the drug clopidogrel. However, unlike classical thrombolytics, the vaccine is used once. Since many patients neglect the doctor's recommendations or simply forget to take the drug on time, the absence of the need for constant drug intake becomes a tangible advantage.
Scientists hope that in 5-10 years they will be able to bring their development to the stage of clinical trials in humans. However, they note that there is still a lot of work to be done for this: it is necessary to make sure that the product is safe for the human body, because the formation of the immune response in humans and mice differs significantly.
Article by Kawano et al. Therapeutic Vaccine Against S100A9 (S100 Calcium-Binding Protein A9) Inhibits Thrombosis Without Increasing the Risk of Bleeding in Ischemic Stroke in Mice published in Hypertension AHA Journal.
Anastasia Poznyak, portal "Eternal Youth" http://vechnayamolodost.ru / based on the materials of the American Heart Association: Experimental vaccine may reduce post-stroke blood clot risk.